Luminex Corporation Achieves Milestone by Shipping its 10,000th Instrument
22 Jul 2013Luminex Corporation has announced it has passed a major milestone by shipping its 10,000th multiplexing instrument. This milestone was achieved by shipping a MAGPIX® instrument to Dr. Kimberle Chapin at the Rhode Island Hospital in Providence, R.I., the largest hospital and only Level I trauma center in the state. This MAGPIX instrument will be used initially for assay validation of Luminex's xTAG® Gastrointestinal Pathogen Panel.
"Shipping our 10,000th instrument is an achievement that every Luminex employee is very proud of," said Patrick J. Balthrop, president and chief executive officer of Luminex. "The substantial installed base of Luminex instruments is a testament to the flexibility of our xMAP® Technology and to the open architecture upon which our customers and partners can build their assays. It is gratifying to know that our 10,000th instrument will be used by Dr. Kimberle Chapin and her excellent team. The ability to streamline gastroenteritis testing and deliver comprehensive, timely results is important to laboratories across the country."
Since shipping its first Luminex® 100™ multiplexing instrument, Luminex has continued to drive innovation in multiplexing products and services to the global healthcare and life science research communities. Luminex is known for developing many first-to-market molecular assays, such as the first multiplex cystic fibrosis assay, the first respiratory viral panel and most recently the first gastrointestinal pathogen panel. Luminex's portfolio of multiplexing instruments and assays addresses a broad range of laboratory and budgetary needs for life science research, clinical diagnostics, and biosurveillance. The instrument line includes the 100-plex Luminex 100/200, the economical 50-plex MAGPIX and the high-throughput, 500-plex FLEXMAP 3D® systems.
Rhode Island Hospital is the principal teaching hospital of The Warren Alpert Medical School of Brown University.
Related Products
Request Quote for All Products
Luminex® 200™Multiplexing Instrument
LuminexThe Luminex® 200™ detects up to 100 protein or nucleic acid analytes from a single aliquot of sample in a single reaction well, enabling you to generate more data while saving sample, time, and reagents. With more than 11,000 units sold globally to date, the Luminex 100/200 is the established standard in multiplexing instrumentation. The xMAP® multiplexing platform is composed of an instrument and associated reagents: The Luminex 200 instrument is based on the principles of flow cytometry, which integrates key xMAP detection components such as lasers, optics, fluidics, and high-speed digital signal processors. xMAP microspheres are a family of fluorescently dyed carboxylated polystyrene microspheres that act as both the surface for the solution phase assay and the spectral identifier that the instrument detects. The open architecture of xMAP Technology enables users to build custom multiplex assays or select from a broad menu commercially available kits. Instrument Details: Multiplex Capacity: Up to 100 non-magnetic; 80 magnetic Microtiter Plate: 96 well Throughput: ~40 min/96-well plate (up to 12,800 tests per hour) Dynamic Range: 3.5 logs Sensitivity: Detects a minimum of 1,000 fluorochromes of phycoerythrin (PE) per xMAP microsphere Optics: Lasers/APDs/PMTs Hardware: Flow Cytometry based Software: xPONENT® Software supports protocol-based data acquisition with robust data regression analysis Dimensions: All components combined (Analyzer, XY Platform and Sheath Delivery System) 26.5" W x 23.5" D x 12.5" H (67.3 cm W x 59.7 cm D x 31.8 cm H) Weight: All components combined (Analyzer, XY Platform and Sheath Delivery System) 113 lbs (49 kg) xMAP Reagent Compatibility: Magnetic and nonmagnetic microspheres